{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:41:27Z","timestamp":1783338087857,"version":"3.54.6"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In patients with late-onset Pompe disease (LOPD), the efficacy of the enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase (rhGAA) is difficult to evaluate, due to the clinical heterogeneity and the small sample sizes in published studies. Therefore, we conduct a systematic literature review and meta-analysis of the literature to evaluate the efficacy of ERT in LOPD patients considering the walking distance, respiratory function and muscle strength. Particularly, six-minute walk test (6MWT), forced vital capacity (FVC), medical research council (MRC) grading, quantitative muscle testing (QMT), and quick motor function test (QMFT) were outcomes of interest. Overall, 619 studies were identified in PubMed, EMBASE and by manual search on July 18th, 2020. After an initial assessment, 16 studies were included in the meta-analysis, containing clinical data from 589 patients with LOPD. For the 6MWT, 419 patients were analyzed. Walking distance improved on average, 32.2\u00a0m greater during the observed period (<jats:italic>p<\/jats:italic>\u2009=\u20090.0003), compared to the distance at the baseline. The meta-analysis did not show any improvement in FVC and only a tendency towards better muscle strength after treatment with ERT, but the difference was not statistically significant. In conclusion, the available data showed that ERT has a significant beneficial efficacy in the improvement of walking distance in LOPD patients and a non-significant improvement of muscle strength. No improvement in respiratory capacity was found. More prospective and controlled trials are needed to demonstrate a clear clinical benefit of ERT.<\/jats:p>","DOI":"10.1007\/s00415-021-10526-5","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T19:08:51Z","timestamp":1618340931000},"page":"733-741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis"],"prefix":"10.1007","volume":"269","author":[{"given":"Berli","family":"Sarah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Giovanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keller","family":"Emanuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najia","family":"Nadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitale","family":"Jos\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pagnamenta","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"issue":"15","key":"10526_CR1","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med 362(15):1396\u20131406","journal-title":"N Engl J Med"},{"issue":"3","key":"10526_CR2","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","volume":"32","author":"M Dasouki","year":"2014","unstructured":"Dasouki M, Jawdat O, Almadhoun O, Pasnoor M, McVey AL, Abuzinadah A et al (2014) Pompe disease: literature review and case series. Neurol Clin 32(3):751\u2013776","journal-title":"Neurol Clin"},{"issue":"23 Suppl 2","key":"10526_CR3","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1212\/WNL.0b013e31818da93f","volume":"71","author":"B Bembi","year":"2008","unstructured":"Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L et al (2008) Management and treatment of glycogenosis type II. Neurology 71(23 Suppl 2):S12-36","journal-title":"Neurology"},{"key":"10526_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-90-481-2813-6_4","volume":"652","author":"SIP Pascual","year":"2009","unstructured":"Pascual SIP (2009) Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme. Adv Exp Med Biol 652:39\u201346","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10526_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","volume":"106","author":"TT Patel","year":"2012","unstructured":"Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS (2012) The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab 106(3):301\u2013309","journal-title":"Mol Genet Metab"},{"issue":"9646","key":"10526_CR6","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJJ (2008) Pompe\u2019s disease. Lancet Lond Engl 372(9646):1342\u20131353","journal-title":"Lancet Lond Engl"},{"issue":"1\u20132","key":"10526_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","volume":"119","author":"A van der Ploeg","year":"2016","unstructured":"van der Ploeg A, Carlier PG, Carlier R-Y, Kissel JT, Schoser B, Wenninger S et al (2016) Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY Study. Mol Genet Metab 119(1\u20132):115\u2013123","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10526_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10545-014-9751-2","volume":"38","author":"JC van der Meijden","year":"2015","unstructured":"van der Meijden JC, G\u00fcng\u00f6r D, Kruijshaar ME, Muir ADJ, Broekgaarden HA, van der Ploeg AT (2015) Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease. J Inherit Metab Dis 38(3):495\u2013503","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10526_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, Corzo D, Leslie ND, Gruskin D, van der Ploeg A, Clancy JP et al (2009) Early treatment with alglucosidase alfa prolongs long term survival of infants with Pompe disease. Pediatr Res 66(3):329\u2013335","journal-title":"Pediatr Res"},{"issue":"4","key":"10526_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","volume":"260","author":"A Toscano","year":"2013","unstructured":"Toscano A, Schoser B (2013) Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 260(4):951\u2013959","journal-title":"J Neurol"},{"issue":"4","key":"10526_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K et al (2017) Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol 264(4):621\u2013630","journal-title":"J Neurol"},{"issue":"6","key":"10526_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, Lafor\u00eat P, Angelini C, Lachmann RH et al (2017) European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol 24(6):768-e31","journal-title":"Eur J Neurol"},{"issue":"1","key":"10526_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/jimd.12027","volume":"42","author":"J Milverton","year":"2019","unstructured":"Milverton J, Newton S, Merlin T (2019) The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: a systematic review. J Inherit Metab Dis 42(1):57\u201365","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"10526_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"key":"10526_CR15","unstructured":"Introduction to Meta-Analysis | Wiley [Internet]. Wiley.com. Available from: https:\/\/www.wiley.com\/en-us\/Introduction+to+Meta+Analysis-p-9780470057247 (accessed 7 Oct 2020)"},{"issue":"6","key":"10526_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10545-010-9204-5","volume":"33","author":"S Ravaglia","year":"2010","unstructured":"Ravaglia S, Pichiecchio A, Ponzio M, Danesino C, Saeidi Garaghani K, Poloni GU et al (2010) Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. J Inherit Metab Dis 33(6):737\u2013745","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10526_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","volume":"257","author":"S Strothotte","year":"2010","unstructured":"Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257(1):91\u201397","journal-title":"J Neurol"},{"issue":"6","key":"10526_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","volume":"33","author":"B Bembi","year":"2010","unstructured":"Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R et al (2010) Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 33(6):727\u2013735","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"10526_CR19","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E et al (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259(5):952\u2013958","journal-title":"J Neurol"},{"issue":"7","key":"10526_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1750-1172-7-73","volume":"26","author":"JM de Vries","year":"2012","unstructured":"de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M et al (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 26(7):73","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10526_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT van der Ploeg","year":"2012","unstructured":"van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ et al (2012) Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab 107(3):456\u2013461","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10526_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","volume":"35","author":"C Regnery","year":"2012","unstructured":"Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B et al (2012) 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 35(5):837\u2013845","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10526_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA et al (2014) Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 37(6):945\u2013952","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10526_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","volume":"117","author":"KM Stepien","year":"2016","unstructured":"Stepien KM, Hendriksz CJ, Roberts M, Sharma R (2016) Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years. Mol Genet Metab 117(4):413\u2013418","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10526_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/nan.12414","volume":"44","author":"M Ripolone","year":"2018","unstructured":"Ripolone M, Violano R, Ronchi D, Mondello S, Nascimbeni A, Colombo I et al (2018) Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Neuropathol Appl Neurobiol 44(5):449\u2013462","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"10526_CR26","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10545-018-0166-3","volume":"41","author":"JC van der Meijden","year":"2018","unstructured":"van der Meijden JC, Kruijshaar ME, Harlaar L, Rizopoulos D, van der Beek NAME, van der Ploeg AT (2018) Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. J Inherit Metab Dis 41(6):1205\u20131214","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"10526_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ymgme.2019.07.013","volume":"128","author":"E Fern\u00e1ndez-Sim\u00f3n","year":"2019","unstructured":"Fern\u00e1ndez-Sim\u00f3n E, Carrasco-Rozas A, Gallardo E, Gonz\u00e1lez-Quereda L, Alonso-P\u00e9rez J, Belmonte I et al (2019) Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT. Mol Genet Metab 128(1\u20132):129\u2013136","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10526_CR28","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s12325-019-00926-5","volume":"36","author":"M Filosto","year":"2019","unstructured":"Filosto M, Cotti Piccinelli S, Ravaglia S, Servidei S, Moggio M, Musumeci O et al (2019) Assessing the role of anti rh-GAA in modulating response to ERT in a late-onset pompe disease cohort from the Italian GSDII study group. Adv Ther 36(5):1177\u20131189","journal-title":"Adv Ther"},{"issue":"4","key":"10526_CR29","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/jcsm.12555","volume":"11","author":"C Nu\u00f1ez-Peralta","year":"2020","unstructured":"Nu\u00f1ez-Peralta C, Alonso-P\u00e9rez J, Llauger J, Segovia S, Montesinos P, Belmonte I et al (2020) Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles. J Cachexia Sarcopenia Muscle 11(4):1032\u20131046. https:\/\/doi.org\/10.1002\/jcsm.12555","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"8","key":"10526_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1172-8-49","volume":"27","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug I, D\u2019Agostino RB, Hagemans MLC, van Doorn PA et al (2013) Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 27(8):49","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10526_CR31","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00415-013-6980-5","volume":"260","author":"T Hundsberger","year":"2013","unstructured":"Hundsberger T, Rohrbach M, Kern L, R\u00f6sler KM (2013) Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. J Neurol 260(9):2279\u20132285","journal-title":"J Neurol"},{"issue":"8","key":"10526_CR32","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.nmd.2015.04.006","volume":"25","author":"B Schoser","year":"2015","unstructured":"Schoser B, Lafor\u00eat P, Kruijshaar ME, Toscano A, van Doorn PA, van der Ploeg AT et al (2015) 208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26\u201328 September 2014. Neuromuscul Disord NMD 25(8):674\u2013678","journal-title":"Neuromuscul Disord NMD"},{"issue":"1","key":"10526_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99(1):26\u201333","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10526_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","volume":"38","author":"CM van Gelder","year":"2015","unstructured":"van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJJ (2015) Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis 38(2):305\u2013314","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10526_CR35","doi-asserted-by":"publisher","first-page":"I29","DOI":"10.1186\/1755-8166-7-S1-I29","volume":"7","author":"M Muranjan","year":"2014","unstructured":"Muranjan M (2014) Enzyme replacement therapy for lysosomal storage disorders in India. Mol Cytogenet 7(1):I29","journal-title":"Mol Cytogenet"},{"issue":"1","key":"10526_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","volume":"149","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC-H, Waterson J et al (2006) Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 149(1):89\u201397","journal-title":"J Pediatr."},{"issue":"3","key":"10526_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mus.22329","volume":"45","author":"EJ Cupler","year":"2012","unstructured":"Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ et al (2012) Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 45(3):319\u2013333","journal-title":"Muscle Nerve"},{"issue":"2","key":"10526_CR38","first-page":"3","volume":"24","author":"JE Davison","year":"2020","unstructured":"Davison JE (2020) Advances in diagnosis and management of Pompe disease. J Mother Child 24(2):3\u20138","journal-title":"J Mother Child"},{"issue":"1","key":"10526_CR39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1750-1172-8-160","volume":"8","author":"R Lachmann","year":"2013","unstructured":"Lachmann R, Schoser B (2013) The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis 8(1):160","journal-title":"Orphanet J Rare Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10526-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10526-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10526-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T15:13:50Z","timestamp":1642778030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10526-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10526"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10526-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"12 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No ethical approval was needed. All studies in this review have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Data from previously published studies, in which informed consent was obtained were retrieved and analyzed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All the authors of this manuscript have been included and we warrant that nobody who qualifies for authorship has been excluded. We agree to its submission to the Journal of Neurology and, if accepted, to its publication in this journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}